[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632407":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":22,"locations":28,"responsibleParty":180,"collaborators":21,"id":182,"slug":183,"hasResults":184,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":21,"eligibilityCriteria":188,"healthyVolunteers":184,"sex":189,"minAge":190,"maxAge":191,"enrollmentInfo":192,"targetDuration":21,"studyType":195,"phases":196,"briefSummary":198,"conditions":199,"keywords":201,"overallStatus":65,"whyStopped":21,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":214},{"fullName":5,"class":6},"Acurx Pharmaceuticals Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Ibezapolstat","EXPERIMENTAL","Active investigational antibacterial agent",[13],"Drug: Ibezapolstat",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Ibezapolstat 450 mg po Q12H x14 days",[9],[20],"ACX-362E",null,[23],{"name":24,"role":25,"phone":26,"phoneExt":21,"email":27},"Dee Rodriguez","CONTACT","7742665290","dee.rodriguez@acurxpharma.com",[29,43,53,63,73,82,91,101,111,121,131,140,150,160,170],{"facility":30,"status":31,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":21},"UC Davis Medical Center","NOT_YET_RECRUITING","Sacramento","California","95817","United States","US",{"type":38,"coordinates":39},"Point",[40,41],-121.4944,38.58157,{"lat":41,"lon":40},{"facility":44,"status":31,"city":45,"state":46,"zip":47,"country":35,"countryCode":36,"cosmosGeoPoint":48,"geoPoint":52,"contacts":21},"Gastroenterolgy Center of Conneticut","Hamden","Connecticut","06518",{"type":38,"coordinates":49},[50,51],-72.89677,41.39593,{"lat":51,"lon":50},{"facility":54,"status":31,"city":55,"state":56,"zip":57,"country":35,"countryCode":36,"cosmosGeoPoint":58,"geoPoint":62,"contacts":21},"Florida International Medical Research","Coral Gables","Florida","33134",{"type":38,"coordinates":59},[60,61],-80.26838,25.72149,{"lat":61,"lon":60},{"facility":64,"status":65,"city":66,"state":56,"zip":67,"country":35,"countryCode":36,"cosmosGeoPoint":68,"geoPoint":72,"contacts":21},"L&A Morales Healthcare, Inc","RECRUITING","Hialeah","33012",{"type":38,"coordinates":69},[70,71],-80.27811,25.8576,{"lat":71,"lon":70},{"facility":74,"status":31,"city":75,"state":56,"zip":76,"country":35,"countryCode":36,"cosmosGeoPoint":77,"geoPoint":81,"contacts":21},"San Marcus Research Clinc, Inc","Miami Lakes","33014",{"type":38,"coordinates":78},[79,80],-80.30866,25.90871,{"lat":80,"lon":79},{"facility":83,"status":31,"city":84,"state":56,"zip":85,"country":35,"countryCode":36,"cosmosGeoPoint":86,"geoPoint":90,"contacts":21},"Belis Delgado, MD PA","Miami Springs","33166",{"type":38,"coordinates":87},[88,89],-80.2895,25.82232,{"lat":89,"lon":88},{"facility":92,"status":31,"city":93,"state":94,"zip":95,"country":35,"countryCode":36,"cosmosGeoPoint":96,"geoPoint":100,"contacts":21},"Infectious Disease Consultants of Georgia","Athens","Georgia","30606",{"type":38,"coordinates":97},[98,99],-83.37794,33.96095,{"lat":99,"lon":98},{"facility":102,"status":65,"city":103,"state":104,"zip":105,"country":35,"countryCode":36,"cosmosGeoPoint":106,"geoPoint":110,"contacts":21},"Snake River Research PLLC","Idaho Falls","Idaho","83404",{"type":38,"coordinates":107},[108,109],-112.03414,43.46658,{"lat":109,"lon":108},{"facility":112,"status":31,"city":113,"state":114,"zip":115,"country":35,"countryCode":36,"cosmosGeoPoint":116,"geoPoint":120,"contacts":21},"Endevour Health","Skokie","Illinois","60077",{"type":38,"coordinates":117},[118,119],-87.73339,42.03336,{"lat":119,"lon":118},{"facility":122,"status":31,"city":123,"state":124,"zip":125,"country":35,"countryCode":36,"cosmosGeoPoint":126,"geoPoint":130,"contacts":21},"Newton-Wellesley Hospital","Newton","Massachusetts","02462",{"type":38,"coordinates":127},[128,129],-71.20922,42.33704,{"lat":129,"lon":128},{"facility":132,"status":31,"city":133,"state":124,"zip":134,"country":35,"countryCode":36,"cosmosGeoPoint":135,"geoPoint":139,"contacts":21},"University of Massachusetts Memorial Healthcare","Worcester","01655",{"type":38,"coordinates":136},[137,138],-71.80229,42.26259,{"lat":138,"lon":137},{"facility":141,"status":31,"city":142,"state":143,"zip":144,"country":35,"countryCode":36,"cosmosGeoPoint":145,"geoPoint":149,"contacts":21},"Henry Ford Hospital","Detroit","Michigan","48202",{"type":38,"coordinates":146},[147,148],-83.04575,42.33143,{"lat":148,"lon":147},{"facility":151,"status":31,"city":152,"state":153,"zip":154,"country":35,"countryCode":36,"cosmosGeoPoint":155,"geoPoint":159,"contacts":21},"DiGiovanna Institute for Medical Education and Research","Massapequa","New York","11758",{"type":38,"coordinates":156},[157,158],-73.47429,40.68066,{"lat":158,"lon":157},{"facility":161,"status":31,"city":162,"state":163,"zip":164,"country":35,"countryCode":36,"cosmosGeoPoint":165,"geoPoint":169,"contacts":21},"Romano, Pontzer & Associated","Pittsburgh","Pennsylvania","15215",{"type":38,"coordinates":166},[167,168],-79.99589,40.44062,{"lat":168,"lon":167},{"facility":171,"status":31,"city":172,"state":173,"zip":174,"country":35,"countryCode":36,"cosmosGeoPoint":175,"geoPoint":179,"contacts":21},"University of Utah","Salt Lake City","Utah","84115",{"type":38,"coordinates":176},[177,178],-111.89105,40.76078,{"lat":178,"lon":177},{"type":181,"investigatorFullName":21,"investigatorTitle":21,"investigatorAffiliation":21,"oldNameTitle":21,"oldOrganization":21},"SPONSOR","100632407","phase-2-acx-362e-ibezapolstat-for-oral-treatment-of-recurrent-clostridioides-difficile-infection-100632407",false,"NCT07513285","ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile Infection","A Phase 2 Interventional, Open-Label, Single-Arm Trial of Oral Ibezapolstat (ACX-362E) for Treatment and Reduction of Recurrent Clostridioides Difficile Infection in Patients With Multiple Recurrent Infections (IBZ-PATHFINDER)","Inclusion Criteria:\n\n* Confirmed diagnosis of CDI as defined by 1) the presence of diarrhea, defined as passage of ≥ 3 UBMs within 24 hours before study Day 1, AND 2) a stool test result positive for the presence of C. difficile free toxins\n* Three or more CDI episodes in the past 12 months, including the current episode, with each episode defined as ≥ 3 unformed stools in 24 hours associated with positive C. difficile toxin test.\n* At least 1 of the protocol-qualifying prior CDI episodes, not including the current episode, has been treated with oral vancomycin or with fidaxomicin\n\nExclusion Criteria:\n\n* Severe, complicated, or life-threatening fulminant CDI with evidence of hypotension (systolic blood pressure \\\u003C 90 mmHg), septic shock, peritoneal signs or ileus, or toxic megacolon\n* Received more than 24 hours of dosing with antibiotics for the current CDI episode:\n* Received a live biotherapeutic product (LBP) (Rebyota® or Vowst™) within the past 12 weeks\n* Received or current use of anti-C. difficile antibodies, eg, IV immunoglobulin \\[IVIG\\], bezlotoxumab\n* Active inflammatory bowel disease (Crohn's disease, ulcerative colitis) with chronic diarrhea within 12 weeks before Baseline, or with a history of symptoms \\> 12 weeks before Baseline without evidence of mucosal healing on colonoscopy within the past year.\n* Active irritable bowel syndrome with chronic diarrhea in the past 12 weeks.\n* Active gastroenteritis because of Salmonella, Shigella, Escherichia coli 0157H7, Yersinia or Campylobacter, other bacteria, a parasite, or a virus within the past 2 weeks\n* Major GI surgery (eg, significant bowel resection) within 3 months of enrollment (does not include appendectomy or cholecystectomy).\n* Known current history of a severely compromised immune system","ALL","18 Years","90 Years",{"count":193,"type":194},20,"ESTIMATED","INTERVENTIONAL",[197],"PHASE2","Single-arm trial to evaluate the safety and efficacy of ACX-362E \\[ibezapolstat\\] in patients with recurrent C. difficile infection (CDI).",[200],"Clostridium Difficile Infection Recurrence",[202,203,204],"Clostridioides difficile","Cdiff","Recurrent Clostridioides difficile","2026-08-10",{"date":207,"type":208},"2026-08-12","ACTUAL",{"date":210,"type":208},"2026-08-06",{"date":212,"type":194},"2027-11-24",{"name":5,"class":6},15]